Ofirmev

Ofirmev is a brand name of acetaminophen, approved by the FDA in the following formulation(s):

OFIRMEV (acetaminophen - solution; iv (infusion))

• 
  Manufacturer: CADENCE PHARMS
  
  Approval date: November 2, 2010
  
  Strength(s): 1000MG/100ML (10MG/ML) ^[RLD]

Has a generic version of Ofirmev been approved?

No. There is currently no therapeutically equivalent version of Ofirmev available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ofirmev. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Stable liquid paracetamol compositions, and method for preparing same
  Patent 6,028,222
  Issued: February 22, 2000
  Inventor(s): Dietlin; Francois & Fredj; Daniele
  Assignee(s): SCR Pharmatop
  Novel stable paracetamol compositions for use in therapeutic chemistry and specifically galenic pharmacy are disclosed. The compositions contain a solution of paracetamol in an aqueous solvent combined with a buffer having a pH of 4 to 8, and a free radical capturing agent. A water-insoluble inert gas is carefully bubbled through the aqueous solvent to remove oxygen from the medium. Said compositions may also be combined with a centrally or peripherally acting analgesic agent, and are provided as injectable compositions for relieving pain.
  
  Patent expiration dates:
  
  
  • August 5, 2017
    
    ✓ 
    Drug product
  
  



• 
  Method for obtaining aqueous formulations of oxidation-sensitive active principles
  Patent 6,992,218
  Issued: January 31, 2006
  Inventor(s): Dietlin; Francois & Fredj; Daniele
  Assignee(s): Pharmatop SCR
  A method for obtaining aqueous formulations with easily oxidizable active principles, notably phenols, stable over a prolonged period, comprising subjecting them to extreme deoxygenation by bubbling with an inert gas and/or placing wider vaccum, protecting them against possible resorption of oxygen by keeping them under an inert gas atmosphere, by filling, under inert gas, into bottles previously cleared of air by insufflation with inert gas, then subjecting them, while stoppering, to low pressure as obtained in the bottle, of 65,000 Pa maximum, to obtain aqueous solutions having a residual oxygen concentration in the solution below 2 ppm, and preferably of the order of 1 ppm and even 0.5 ppm useful as injectable preparations having an oxygen concentration in the solution below 2 ppm.
  
  Patent expiration dates:
  
  
  • June 6, 2021
    
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • November 2, 2013 - NEW PRODUCT
  
  

See also...

• Ofirmev Consumer Information (Drugs.com)
• Ofirmev Injection Consumer Information (Wolters Kluwer)
• Ofirmev Advanced Consumer Information (Micromedex)
• Acetaminophen Consumer Information (Drugs.com)
• Acetaminophen Capsules Consumer Information (Wolters Kluwer)
• Acetaminophen Chewable Tablets Consumer Information (Wolters Kluwer)
• Acetaminophen Controlled-Release Tablets Consumer Information (Wolters Kluwer)
• Acetaminophen Dispersible Tablets Consumer Information (Wolters Kluwer)
• Acetaminophen Drops Consumer Information (Wolters Kluwer)
• Acetaminophen Elixir Consumer Information (Wolters Kluwer)
• Acetaminophen Gel Syrup Consumer Information (Wolters Kluwer)
• Acetaminophen Injection Consumer Information (Wolters Kluwer)
• Acetaminophen Suppositories Consumer Information (Wolters Kluwer)
• Acetaminophen Suspension Consumer Information (Wolters Kluwer)
• Acetaminophen Suspension Drops Consumer Information (Wolters Kluwer)
• Tempra 1 Drops Consumer Information (Wolters Kluwer)
• Acetaminophen Quickmelt Consumer Information (Cerner Multum)
• Mapap Infants' Consumer Information (Cerner Multum)
• Tylenol Arthritis Gelcap Consumer Information (Cerner Multum)
• Acetaminophen Consumer Information (Cerner Multum)
• Acetaminophen rectal Consumer Information (Cerner Multum)
• Children's Acetaminophen Advanced Consumer Information (Micromedex)
• Children's Acetaminophen Bubble Gum Flavor Advanced Consumer Information (Micromedex)
• Children's Acetaminophen Cherry Flavor Advanced Consumer Information (Micromedex)
• Children's Acetaminophen Grape Flavor Advanced Consumer Information (Micromedex)
• Children's Acetaminophen Suspension Bubble Gum Flavor - Ages 2 To 11 Advanced Consumer Information (Micromedex)
• Children's Acetaminophen Suspension Cherry Flavor Advanced Consumer Information (Micromedex)
• Children's Acetaminophen Suspension Grape Flavor - Ages 2 To 11 Advanced Consumer Information (Micromedex)
• Comtrex Sore Throat Relief Advanced Consumer Information (Micromedex)
• Acetaminophen Intravenous Advanced Consumer Information (Micromedex)
• Acetaminophen Oral, Rectal Advanced Consumer Information (Micromedex)
• Acetaminophen, sodium bicarbonate, and citric acid Advanced Consumer Information (Micromedex)
• Acetaminophen AHFS DI Monographs (ASHP)